British journal o/ Haernatology, 1991, 77, 80-86
Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor$ in patients with myelofibrosis with myeloid metaplasia MARIE-CLAIREMARTYRE,’H E N R IMACDELENAT,’MARIE-CLAUDE BRYCKAERT,’ CHRISTINELAINE-BIDRON’ A N D F A B I E N C A L V O ‘Unite ~ 196 ZNSERM. Znstitut Curie, Section de Biologie, 75005 Paris. 2Laboratoire de Radiopathologie. Znstitut Curie. 75005 Paris, jUnite 150 ZNSERM, Hbpital Lariboisiere, 7 5010 Paris, and 4Laboratoire de Pharmacologie Experimentale et Clinique. Znstitut de Genktique MolPculairc, Hbpital Saint-Louis. 75010 Paris. France Received 31 May 1990; accepted for publication 4 September 1990
Summary. Platelet-derived growth factor (PDGF) is thought to play some role in the genesis of fibrosis associated with myeloproliferative disorders. In addition, transforming growth factor-/I (TGF-p) has been confirmed to promote fibrotic process. Both PDGF and TGF-/I have been shown to cooperate with epidermal growth factor (EGF) in regulating the growth of human marrow fibroblasts. All three are contained in platelet a-granules. We report the results ofa study in patients with myelofibrosis with myeloid metaplasia (MMM). We evaluated PDGF. TGF-,4 and EGF-like activities in circulating platelets from patients compared to healthy subjects. In contrast to EGF-like intraplatelet levels which were similar in patients and in normal donors (1-4 ng/lOy platelets), we found constantly higher values for both PDGF and TGF-P in MMM patients. In both radioimmunoassay (RIA) and assay for mitogenic
activity on human bone marrow fibroblasts, PDGF levels were increased on the average 2-3.5-fold over the levels found in normal donors ( P < O 4 1 and P
Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor$ in patients with myelofibrosis with myeloid metaplasia MARIE-CLAIREMARTYRE,’H E N R IMACDELENAT,’MARIE-CLAUDE BRYCKAERT,’ CHRISTINELAINE-BIDRON’ A N D F A B I E N C A L V O ‘Unite ~ 196 ZNSERM. Znstitut Curie, Section de Biologie, 75005 Paris. 2Laboratoire de Radiopathologie. Znstitut Curie. 75005 Paris, jUnite 150 ZNSERM, Hbpital Lariboisiere, 7 5010 Paris, and 4Laboratoire de Pharmacologie Experimentale et Clinique. Znstitut de Genktique MolPculairc, Hbpital Saint-Louis. 75010 Paris. France Received 31 May 1990; accepted for publication 4 September 1990
Summary. Platelet-derived growth factor (PDGF) is thought to play some role in the genesis of fibrosis associated with myeloproliferative disorders. In addition, transforming growth factor-/I (TGF-p) has been confirmed to promote fibrotic process. Both PDGF and TGF-/I have been shown to cooperate with epidermal growth factor (EGF) in regulating the growth of human marrow fibroblasts. All three are contained in platelet a-granules. We report the results ofa study in patients with myelofibrosis with myeloid metaplasia (MMM). We evaluated PDGF. TGF-,4 and EGF-like activities in circulating platelets from patients compared to healthy subjects. In contrast to EGF-like intraplatelet levels which were similar in patients and in normal donors (1-4 ng/lOy platelets), we found constantly higher values for both PDGF and TGF-P in MMM patients. In both radioimmunoassay (RIA) and assay for mitogenic
activity on human bone marrow fibroblasts, PDGF levels were increased on the average 2-3.5-fold over the levels found in normal donors ( P < O 4 1 and P
